66346-87-0

Basic information

• Product Name: 6-chloro-5-Methyl-3,6-dihydropyridazin-3-aMine
• Synonyms: 3-PyridazinaMine,6-chloro-5-Methyl-;6-chloro-5-Methylpyridazin-3-aMine;6-Chloro-5-methyl-3-pyridazinamine;Pyridazine, 6-amino-3-chloro-4-methyl-(6CI,7CI);(6-Chloro-5-methylpyridazin-3-yl)amine;6-Amino-3-chloro-4-methylpyridazine
• CAS NO: 66346-87-0
• Molecular Formula: C₅H₆ClN₃
• Molecular Weight: 146
• Mol File: 66346-87-0.mol
• Article Data: 28

Chemical Properties

• Melting Point: 190-191 °C(Solv: ethanol (64-17-5))
• Boiling Point: 358.423 °C at 760 mmHg
• Flash Point: 170.569 °C
• Appearance: /
• Density: 1.35 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.98±0.10(Predicted)
• CAS DataBase Reference: 6-chloro-5-Methyl-3,6-dihydropyridazin-3-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-5-Methyl-3,6-dihydropyridazin-3-aMine(66346-87-0)
• EPA Substance Registry System: 6-chloro-5-Methyl-3,6-dihydropyridazin-3-aMine(66346-87-0)

Safety Data

• Hazardous Substances Data: 66346-87-0(Hazardous Substances Data)

Usage

Uses

6-CHLORO-5-METHYLPYRIDAZIN-3-AMINE is a useful research chemical.

Upstream product

• 19064-64-3 3,6-dichloro-4-methylpyridazine 
• 66530-56-1 (6-chloro-5-methylpyridazin-3-yl)hydrazine 

Downstream Products

• 91241-39-3 4-amino-N-(6-chloro-5-methyl-pyridazin-3-yl)-benzenesulfonamide 
• 259106-36-0 (6-chloro-7-methyl-2-phenyl-imidazo[1,2-b]pyridazin-3-yl)-acetic acid ethyl ester 
• 483367-44-8 6-chloro-7-methyl-2-phenylimidazo[1,2-b]pyridazine 
• 108784-41-4 6-chloro-3-methoxy-7-methyl-2-phenylimidazo<1,2-b>pyridazine 
• 17412-19-0 6-chloro-7-methylimidazo[1,2-b]pyridazine 
• 1025066-16-3 3-bromo-6-chloro-7-methyl-imidazo[1,2-b]pyridazine 
• 17412-22-5 6-chloro-8-methylimidazo[1,2-b]pyridazine 
• 1186234-46-7 3-[5-(2-fluoro-phenyl)-pyridin-2-yloxy]-azetidine-1-carboxylic acid (4-methyl-pyridazin-3-yl)-amide 
• 1186234-45-6 3-[5-(2-fluoro-phenyl)-pyridin-2-yloxy]-azetidine-1-carboxylic acid (5-methyl-pyridazin-3-yl)-amide 
• 882500-13-2 5-methyl-6-[4-(piperidine-1-sulfonyl)-phenylsulfanyl]-pyridazin-3-ylamine 
• 882500-14-3 4-methyl-6-[4-(piperidine-1-sulfonyl)-phenylsulfanyl]-pyridazin-3-ylamine 
• 93258-21-0 4-amino-N-(6-ethoxy-5-methyl-pyridazin-3-yl)-benzenesulfonamide 
• 104095-05-8 sulfanilic acid-(5-methyl-6-oxo-1,6-dihydro-pyridazin-3-ylamide) 
• 152537-63-8 6-(2,2-diethyl-6-sulfamoyl-1-hexyloxy)-7-methyl[1,2,4]triazolo[1,5-b]pyridazine 

Relevant articles and documents

3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS

Compounds of formula (I) wherein Het1, Het2, R1, R2 and R3 are as defined in the description. Medicaments.

Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)

SMA is an inherited disease that leads to loss of motor function and ambulation and a reduced life expectancy. We have been working to develop orally administrated, systemically distributed small molecules to increase levels of functional SMN protein. Compound 2 was the first SMN2 splicing modifier tested in clinical trials in healthy volunteers and SMA patients. It was safe and well tolerated and increased SMN protein levels up to 2-fold in patients. Nevertheless, its development was stopped as a precautionary measure because retinal toxicity was observed in cynomolgus monkeys after chronic daily oral dosing (39 weeks) at exposures in excess of those investigated in patients. Herein, we describe the discovery of 1 (risdiplam, RG7916, RO7034067) that focused on thorough pharmacology, DMPK and safety characterization and optimization. This compound is undergoing pivotal clinical trials and is a promising medicine for the treatment of patients in all ages and stages with SMA.

COMPOUNDS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS

The present invention provides compounds of formula (I) (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof for use in the treatment, prevention and/or delay of progression of amyotrophic lateral sclerosis (ALS). Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.